The Cardio-Kidney-Metabolic (CKM) concept and early intervention in diabetes

Cardiovascular disease (CVD) continues to impose a heavy burden across populations, driven by the rising prevalence of obesity, diabetes, and related metabolic disorders. Understanding grave need for action to tackle this situation, Novo Nordisk has engaged with a group of prominent cardiologists to heighten awareness on this important health state and to champion the recent CKM concept in cardiology. This series features the perspectives of a few prominent cardiologists, each of whom will provide clinical experience and evidence-based insights on strategies that can enhance patient outcomes and help to address these interconnected challenges. Their voices, when combined, illustrate the significance of early intervention, effective therapies, and a greater awareness of the CKM continuum.

In Part 1, Dr David Quek addresses the growing challenge of obesity and its downstream impact on diabetes, kidney disease, and cardiovascular (CV) health. He highlighted the CKM framework as a practical tool for clinicians to recognise and act on these interconnected risks.